Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

5 Things to Know Before the Stock Market Opens

Stock futures are moving higher this morning after experiencing significant volatility last week amid growing concerns about the possibility of an AI bubble. Stocks rose on Friday after a Federal ...
The Malaysian Reserve

Americans are microdosing obesity drugs, driven by ‘thin is in’ marketing blitz

Loosely regulated online platforms are promoting powerful obesity shots as a universal weight-loss solution. Photographer: ...

Health Care Roundup: Market Talk

Find insight on Novo Nordisk, CSPC Pharmaceutical Group and more in the latest Market Talks covering Health Care.

Weight-loss drugs increasingly marketed for cosmetic use, raising health concerns

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...
WHBL

What other health conditions are weight-loss drugs being used and tested for?

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...